APOE and Alzheimer disease: In addition, as a considerable portion of AD patients are reported having systemic and/or cerebral vascular pathologies, future larger-scale studies incorporating other biomarkers such as APOE genotyping or amyloid scan are warranted to verify the current hypothesis (Lee et al., 2020).